TY  - JOUR 
AU  - Ríos Luci, Carla
AU  - Díaz Rodríguez, María Elena
AU  - Gandullo Sánchez, Lucía
AU  - Díaz-Gil, Laura
AU  - Ocaña, Alberto
AU  - Pandiella Alonso, Atanasio
PY  - 2020
SN  - 0304-3835
UR  - http://hdl.handle.net/10366/171425
AB  - [EN]Small molecule inhibitors (TKIs) of HER2 have demonstrated clinical benefit in HER2-positive breast tumors. One of them, lapatinib, is used once advanced tumors become refractory to the HER2 antibody trastuzumab. Another one, neratinib, has shown...
LA  - eng
PB  - Elsevier
KW  - Breast cancer
KW  - Drug resistance
KW  - HER2
KW  - Lapatinib
KW  - Neratinib
KW  - Breast Neoplasms
KW  - Xenograft Model Antitumor Assays
KW  - Humans
KW  - Quinolines
KW  - DNA Damage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Cell Line
KW  - Antineoplastic Agents
KW  - Protein Kinase Inhibitors
KW  - Drug Resistance
KW  - Apoptosis
KW  - Naphthoquinones
KW  - Gene Expression Profiling
KW  - Pyridines
KW  - Animals
KW  - Imidazoles
KW  - Mice
TI  - Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms
DO  - 10.1016/j.canlet.2019.11.026
T2  - Cancer letters
VL  - 470
M2  - 161
ER  -